Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2/3 × Has results × Bendamustine Hydrochloride × Clear all

Phase

Phase 2 44 Phase 3 24 Phase 1/2 22 Phase 1 5 Phase 4 1 Phase 2/3 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Lymphoma, Large B-Cell, Diffuse 1

Interventions

Magnetic Resonance Spectroscopy 7 Cyclophosphamide 7 Paclitaxel 6 Leucovorin 6 Granulocyte Colony-Stimulating Factor 6 Filgrastim 6 Etoposide 6 Drug Therapy 6 Cisplatin 6 Oxaliplatin 5 Nivolumab 5 Fluorouracil 5 Doxorubicin 5 Carboplatin 5 Bevacizumab 5 Sirolimus 4 Rituximab 4 Radiotherapy, Intensity-Modulated 4 Radiotherapy 4 Melphalan 4 Immunoglobulin G 4 Gemcitabine 4 Docetaxel 4 Disulfides 4 Cytarabine 4 Capecitabine 4 pembrolizumab 3 gallium 68 PSMA-11 3 dexamethasone acetate 3 dexamethasone 21-phosphate 3

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02763319 2025-07-17

B-MIND

Incyte Corporation

Phase 2/3 Completed

453 enrolled 29 charts

Lymphoma, Large B-Cell, Diffuse

Data powered by HemOnc (CC BY 4.0) Colophon ⚡